The Cleave Therapeutics p97 (VCP) inhibitor, CB-5083, was a Ph. I clinical candidate for cancer that was terminated due to vision side effects including causing patients to see unusual colors (dyschromatopsia). In this paper, the authors suggest that the visual impairment was due to the compounds inhibition of the phosphodiesterase-6 (PDE6) [...]
< 1 minute read
Sep. 18, 2021
CB-5083: An Inhibitor of p97/Valosin-Containing Protein
CB-5083
p97/VCP ATPase inhibitor (PDE6 off-target) Ph. I in cancer (discont., dyschromatopsia) from HTS of NIH compound library J. Pharmacol. Exp. Ther., Apr. 30, 2021 Cleave Therapeutics, San Francisco, CA